Navigation Links
BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
Date:3/30/2009

SAN ANTONIO, March 30 /PRNewswire/ -- BioMedical Enterprises, Inc. (BME), a rapidly growing medical device company focused on the clinical development of orthopaedic memory metal implants, announced today that it has appointed Keith M. Peeples as its Vice President, Sales and Marketing.

BME specializes in nitinol implants that contract and compress bone after implantation, bringing bone ends together to promote bone union. The Orthopaedic Staple System (OSS)(TM) of proprietary staples and the patented OSSforce(TM) Controller allow the surgeon to finely control the amount of compression and rate of force application generated on bones, thereby reducing fractures and stimulate bone healing.

"Keith is a proven executive who brings extensive senior level sales and marketing experience to BME, as well as a shared strategic vision to create a leading medical device company," said Kenneth I. Moch, President and CEO of BME. "We are delighted to have Keith as part of our leadership team."

Mr. Peeples brings to BME over 25 years experience in sales, marketing and sales training in the healthcare industry. Prior to joining BME he was Vice President of Sales and Marketing at Advanced Bio-Surfaces, Inc., an orthopedic company that manufactures an interpositional knee implant system. From 1999 to 2006, Mr. Peeples was Vice President of Sales at The ASC Network, which offers a supply solution to physician owned or procedure based centers. From 1995-1998, Mr. Peeples was Director of Sales for North and South America at Medtronic / InStent, a provider of self-expanding nitinol stents for gastroenterology, urology, radiology and peripheral vascular procedures. Mr. Peeples also worked as the Western Regional Sales Manager and as an independent sales representative with Pentax Precision Instrument Corp., a provider of flexible endoscopes, from 1981 to 1995. Mr. Peeples has a B.A. in Biology from the
'/>"/>

SOURCE BioMedical Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
3. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
4. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
5. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
6. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
9. Environmental Tectonics Corporations BioMedical Division Announces New Contract
10. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
11. Verax Biomedical Receives ISO Certification
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3
Other Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 2Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 4Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 5Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 6Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 7Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 8Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 9Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 10Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 11Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 12Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 13Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 14Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 15Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 16Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 17